The scientific interest in spirituality has increased in recent years, paralleled by promising findings on the effects of spiritual experiences induced by psychedelics substances (PS), in the treatment of psychiatric disorders. However, these experiences may also bring challenges, depending on a variety of non-pharmacological variables. This article argues that an undiscerning use of PS to...
Hypoxia and psychedelics, despite their distinct origins, both induce altered states of consciousness and promote neuroplasticity, suggesting a shared underlying mechanism relevant to neuropsychiatric treatment and neurological recovery. Terminal lucidity, the transient resurgence of cognitive function in late-stage dementia, highlights the brain's latent capacity for rapid reorganization, a...
Chris Letheby offers a two-factor account of psychedelic therapy in which the first of these factors is the induction of plasticity on neural, cognitive, and phenomenological levels. The second factor, which Letheby believes is crucial for lasting change, is the discovery of new forms of self-modelling within the psychedelic experience and the appropriate reinforcement thereof in the period of...
Ego dissolution—the experience of losing one’s sense of self—is reported across a range of altered states, including psychedelic intoxication, meditative absorption, traumatic dissociation, and psychotic episodes. This paper proposes a unifying framework for these phenomena by introducing the concept of unlooping: the breakdown of recursive structures that construct and maintain identity....
Czechia has recently approved the medical use of psilocybin, marking a pivotal shift in the country’s drug policy landscape. This development paves the way for regulated therapeutic applications of psilocybin within clinical settings, while simultaneously prompting a timely discussion on the potential uses of psychedelics beyond strictly medical contexts. This commentary first outlines the...
Abstract This article traces the shifting fortunes of for-profit psychedelic medicine through two phases: a boom from 2016 to late 2021, followed by a bust that continued through late 2024. It argues that the forces driving this cycle are best understood through the concept of capitalization, which links present valuations to investor expectations about future earnings. Engaging the...
AbstractBackgroundResearch has shown that psychedelics may have therapeutic potential in treating mental disorders like depression and anxiety. However, the mechanisms and actions underlying their effects are still not fully understood. Similarly, while the significance of mindset and setting in shaping psychedelic experiences and therapeutic outcomes is well established, information about the...
September 7, 2025Mathew Herbert, Brian H. Blanco, Dimitri Perivoliotis et al.
preprint
There is promise for 3,4-Methylenedioxymethamphetamine (MDMA)-assistedpsychotherapy as a highly effective and durable treatment for posttraumatic stress disorder(PTSD). However, the Food and Drug Administration rejected MDMA-assisted psychotherapy inits current form, expressing concerns about the lack of standardization and empirical basis ofpsychotherapy methods. This highlights the need to...
3,4-methelenedioxymethamphetamine (MDMA) can be effective in treating posttraumatic stress disorder (PTSD) in controlled trials, potentially secondary to MDMA’s effects on neural circuits implicated in fear and reward. Although anxiety, stress, and fear-based disorders involve maladaptation of the neural circuits processing fear, threat, and reward, no studies have tested MDMA’s therapeutic...
Mental health disorders (MHD) rank among the top 10 global causes of disease burden, with significant economic and social costs. Current treatments often have limited efficacy or tolerability, and there has been little recent innovation in treatments. In the past decade, clinical research on Psychedelic-Assisted Therapies (PAT) for treating MHD has increased in high-income countries, while most...